Institute of Hospital Hygiene, City of Cologne Hospitals, Cologne, Germany.
National Reference Centre for Staphylococci and Enterococci, Division 13: Nosocomial Pathogens and Antibiotic Resistances, Department of Infectious Diseases, Robert Koch Institute, Wernigerode Branch, Wernigerode, Germany.
J Antimicrob Chemother. 2018 May 1;73(5):1185-1193. doi: 10.1093/jac/dky010.
To investigate an outbreak of linezolid-resistant Staphylococcus epidermidis (LRSE) in an interdisciplinary ICU, linezolid consumption and infection control measures taken.
Routine surveillance of nosocomial infections revealed colonization and infection with LRSE affecting 14 patients during a 15 month period. LRSE isolates were analysed with respect to their clonal relatedness, antimicrobial susceptibility, the presence of cfr and/or mutations in the 23S rRNA, rplC, rplD and rplV genes. cfr plasmids were characterized by Illumina sequencing. Medical records were reviewed and antibiotic consumption was determined.
Molecular typing identified the presence of three different LRSE clusters: PFGE type I/ST168 (n = 5), PFGE type II/ST5 (n = 10) and PFGE type III/ST2 (n = 1). Ten strains harboured the cfr gene; we also detected mutations in the respective ribosomal protein genes. WGS revealed an almost identical 39 kb cfr plasmid obtained from strains of different genetic background (ST2, ST5, ST168) that shows high similarity to the recently published LRSE plasmid p12-02300. Due to an increase in the number of patients treated for infections with MRSA, a significant increase in linezolid usage was noted from January to July 2014 (from 5.55 to 20.41 DDDs/100 patient-days).
Here, we report the molecular epidemiology of LRSE in an ICU. Our results suggest the selection of resistant mutants under linezolid treatment as well as the spread of cfr-carrying plasmids. The reduction of linezolid usage and the strengthening of contact precautions proved to be effective infection control measures.
调查跨学科重症监护病房(ICU)中利奈唑胺耐药表皮葡萄球菌(LRSE)的暴发情况,评估利奈唑胺的使用情况和感染控制措施。
通过常规监测医院感染,在 15 个月期间发现 14 例患者发生了 LRSE 定植和感染。对 LRSE 分离株的克隆相关性、药敏情况、cfr 及/或 23S rRNA、rplC、rplD 和 rplV 基因突变进行分析。采用 Illumina 测序对 cfr 质粒进行特征分析。对病历进行回顾,并确定抗生素的使用情况。
分子分型确定了三种不同的 LRSE 聚类:PFGE 型 I/ST168(n=5)、PFGE 型 II/ST5(n=10)和 PFGE 型 III/ST2(n=1)。10 株携带 cfr 基因,我们还在相应核糖体蛋白基因中检测到突变。全基因组测序(WGS)显示,来自不同遗传背景(ST2、ST5、ST168)菌株的几乎相同的 39kb cfr 质粒,与最近发表的 LRSE 质粒 p12-02300 高度相似。由于治疗耐甲氧西林金黄色葡萄球菌(MRSA)感染的患者数量增加,2014 年 1 月至 7 月利奈唑胺的使用量显著增加(从 5.55 至 20.41DDD/100 患者日)。
本研究报告了 ICU 中 LRSE 的分子流行病学情况。我们的研究结果表明,利奈唑胺治疗选择了耐药突变体,同时 cfr 携带质粒传播。减少利奈唑胺的使用和加强接触预防措施被证明是有效的感染控制措施。